GlyCardial Diagnostics’ technology is based on the quantification of specific protein modifications as a novel and disruptive approach to detect cardiac ischemia

- Technology -

Novel and proprietary method

Based on specific monoclonal antibodies, for the specific detection of target glycosylated forms of Apo J

- Clinical benefits -

Diagnostic and Prognostic Value

Early detection (15-30 minutes from ischemia onset).

Ischemic risk stratification.

- Diagnostic tool benefits -

Monoclonal antibody technology

Allows standardisation and upscaling

Marker with comparably high concentration

Applicable to standard immunochemistry and point-of-care detection technologies